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Abstract
Background Thyroid fine-needle aspiration (FNA) biopsy
is indeterminate or suspicious in up to 30% of cases and
these patients are commonly subjected to at least a diag-
nostic hemithyroidectomy. If malignant on histology, a
completion thyroidectomy is usually performed, which
may be associated with higher morbidity. To determine the
clinical utility of genetic testing in thyroid FNA biopsy, we
conducted a prospective clinical trial.
Methods Four hundred seventeen patients with 455 thy-
roid nodules were enrolled and had genetic testing for
common somatic mutations (BRAF, NRAS, KRAS) and
gene rearrangements (RET/PTC1, RET/PTC3, RAS,
TRK1) by PCR and direct sequencing and by nested PCR,
respectively. The sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of
genetic testing in thyroid FNA biopsy were determined
based on the histologic diagnosis.
Results One hundred twenty-five of 455 thyroid nodule
FNA biopsies were indeterminate or suspicious on cyto-
logic examination. Overall, 50 mutations were identified
(23 BRAF, 4 RET/PTC1, 2 RET/PTC3, 21 NRAS) in the
thyroid FNA biopsies. There were significantly more
mutations detected in malignant thyroid nodules than in
benign (P = 0.0001). For thyroid FNA biopsies that were
indeterminate or suspicious, genetic testing had a sensi-
tivity of 12%, specificity of 98%, PPV of 38%, and NPV of
65%.
Conclusions Genetic testing for somatic mutations in
thyroid FNA biopsy samples is feasible and identifies a
subset of malignant thyroid neoplasms that are indetermi-
nate or suspicious on FNA biopsy. Genetic testing for
common somatic genetic alterations thus could allow for
more definitive initial thyroidectomy in those with positive
results.
Introduction
The number of patients requiring clinical evaluation of
thyroid nodules has dramatically increased over the past
three decades due to the increasing number of thyroid
incidentalomas [1]. Fine-needle aspiration (FNA) biopsy is
the most accurate and cost-effective preoperative test to
distinguish benign from malignant thyroid nodules. Most
thyroid nodules are benign and only about 5% of them have
malignant features on FNA biopsy and cytologic exami-
nation. Unfortunately, FNA biopsy is inconclusive in about
30% of all thyroid nodule biopsies because the cytologic
features are indeterminate (follicular and Hu¨rthle neo-
plasm), suspicious for malignancy but not completely
diagnostic, or nondiagnostic (insufficient cells) upon
cytologic examination. These patients are typically sub-
jected to a diagnostic thyroidectomy to exclude a thyroid
cancer diagnosis. Approximately 20% of patients with
FNA biopsy showing indeterminate cytologic features will
have thyroid cancer on histologic examination and may
require a completion thyroidectomy.
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Although FNA biopsy is accurate for benign and
malignant interpretations, up to 10% of benign cytologic
results may be false negatives and result in delay in diag-
nosis and treatment [2]. Also, significant discordance in the
thyroid FNA biopsy cytologic interpretation has been
reported on secondary review, especially for indeterminate,
nondiagnostic, and suspicious findings [3]. The discor-
dance in thyroid FNA biopsy interpretation can have sig-
nificant management ramifications, ranging from patients
avoiding thyroidectomy to allowing for more definitive
initial surgical treatment in some cases. In order to
decrease the need for unnecessary procedures and the
additional costs incurred for diagnostic and completion
thyroidectomies, new approaches to improving the diag-
nostic accuracy of FNA biopsy are needed.
Thyroid cancer marker research has been an active area
with numerous approaches and candidate markers emerg-
ing but very few markers have been evaluated in a clinical
trial to find whether they would be useful in clinical
practice [4]. Molecular testing for common somatic
mutations is one promising approach that has emerged
because about two-thirds of thyroid cancers of follicular
cell origin have one of the common genetic alterations
(BRAF and RAS point mutations and RET/PTC and
NTRK1 rearrangements), the genetic changes that occur
are usually mutually exclusive events, and most of these
genetic changes are specific to thyroid cancer of follicular
cell origin (BRAF mutation and RET/PTC rearrange-
ments). Somatic genetic alterations in thyroid cancer of
follicular cell origin occur in genes involved in the tyrosine
kinase signaling pathway (tyrosine kinase receptors: RET/
PTC and NTRK1; intracellular signaling proteins: HRAS,
KRAS, NRAS, and BRAF). The most prevalent genetic
alteration is a point mutation in BRAF (V600E), which is
present in approximately 40% of classic papillary thyroid
cancers. RET/PTC and NTRK1 chromosomal rearrange-
ments are present in about 30% and up to 15% of classic
papillary thyroid cancers, respectively [4]. Hotspot muta-
tions in NRAS and KRAS are more common in follicular
thyroid carcinoma but also occur in benign thyroid neo-
plasm at a lower rate.
Several studies have reported that testing for the com-
mon somatic genetic changes in thyroid cancer may be
useful for detecting thyroid cancer in indeterminate and
suspicious thyroid FNA biopsy results [5–15]. Most of
these studies were retrospective, tested for a limited num-
ber of genetic changes, and/or had a relatively small group
of indeterminate, suspicious, and nondiagnostic FNA cytol-
ogy groups. In fact, at the National Cancer Institute State of
the Science Conference on thyroid FNA biopsy, it was
suggested that although promising, there was limited data
to recommend molecular testing for common somatic
genetic alterations as an ancillary test to thyroid FNA
biopsy for indeterminate and suspicious cytologic findings
[16].
In this prospective clinical trial, we wanted to determine
the feasibility and accuracy of molecular testing for a
comprehensive panel of somatic genetic alterations asso-
ciated with thyroid cancer of follicular cell origin in clin-
ical thyroid FNA biopsy samples. We evaluated 455
thyroid nodule FNA biopsy samples from 417 patients
using PCR and direct sequencing for hotspot mutations in
BRAF, NRAS, and KRAS, and nested PCR for RET/PTC1,
RET/PTC3, and NTRK1 rearrangements.
Materials and methods
We recruited 438 subjects to participate in the study from
June 2006 to July 2008 at the University of California, San
Francisco (UCSF); 417 agreed and 21 refused to participate
(Fig. 1). The trial was approved by the Committee on
Human Research at UCSF and registered at clinicaltri-
als.gov. Of the 455 thyroid FNA samples taken for anal-
ysis, 453 had an adequate nucleic acid yield for molecular
testing. The FNA biopsy sample was dispensed into the
TRIzol (Invitrogen, Carlsbad, CA) reagent and stored at
-80C until RNA extraction. The genetic testing results
were not used to make clinical management decisions.
Tissue diagnoses were confirmed by permanent histology,
which was used as the gold standard to determine accuracy.
All the diagnoses were based on the dominant nodule that
was biopsied and not other areas of microscopic papillary
thyroid cancer.
Fig. 1 FNA samples for molecular testing undergoing mutation
analysis
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RNA extraction and cDNA synthesis
Total RNA was extracted using the TRIzol reagent
according to the manufacturer’s protocol. The amount of
total RNA was determined by spectrophotometry using
NanoDrop 3.0 (NanoDrop, Inc., Wilmington, DE). One
microgram of total RNA was reverse transcribed using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).
PCR detection of somatic genetic alterations
Detection of hotspot mutations in BRAF, KRAS,
and NRAS
The samples were tested for BRAF, KRAS, and NRAS
hotspot mutations using PCR amplification with specific
primers (Table 1) and the products were confirmed by gel
electrophoresis. The PCR products were analyzed for the
hotspot mutations by automated direct DNA sequencing.
The PCR amplification reaction was performed using 75 ng
of cDNA template in 2.5 ll 109 PCR buffer, 2.5 ll MgCl2
(25 mM), 0.25 ll dNTP (100 mM/4), 0.625 ll each primer
(20 mM), 0.1 ll BSA (1009), 0.125 ll DNA polymerase
(5 U/ll; AmpliTaq Gold, Applied Biosystems, Foster City,
CA), and RNase-free H2O in a total volume of 25 ll.
PCR products were prepared for direct sequencing using
enzymatic reactions of Exonuclease I (USB Corp., Cleve-
land, OH) and Shrimp Alkaline Phosphatase (USB Corp) to
digest excess primers and dephosphorylate any free
nucleotides. This was carried out using the iCycler at 37C
for 30 min followed by 15 min at 80C. Samples were then
prepared with reverse primers for each hotspot mutation
and sequenced using the ABI BigDye v3.1 dye terminator
sequencing chemistry with the ABI PRISM 3730xl capil-
lary DNA analyzer. The sequences were analyzed to
determine mutation status using Mutation Surveyor v3.10
(SoftGenetics, State College, PA).
Detection of RET/PTC1, RET/PTC3, and NTRK1
chromosomal rearrangements
The presence of RET/PTC1, RET/PTC3, and NTRK1 rear-
rangements in thyroid FNA biopsy samples was tested for
using nested PCR (Table 2). The PCR product was subjected
to gel electrophoresis to determine the presence of the spe-
cific rearrangement. For the RET/PTC1 and RET/PTC3
rearrangements, the PCR amplification reaction was per-
formed using 75 ng of cDNA, 2.5 ll 109 PCR buffer, 2.5 ll
MgCl2 (25 mM), 0.4 ll dNTP (100 mM/4), 0.625 ll each
primer (20 mM), 0.1 ll BSA (1009), 0.125 ll DNA poly-
merase (5 U/ll; AmpliTaq Gold, Applied Biosystems),
and RNase-free H2O in a total volume of 25 ll. Positive
controls for RET/PTC1 and RET/PTC3 were kindly pro-
vided by Dr. Yuri Nikiforov (University of Pittsburgh), and
prior positive samples were used for NTRK1 rearrangement
confirmed with nested PCR.
Statistical analyses
The sensitivity, specificity, PPV, and NPV of genetic
testing in thyroid FNA biopsy were determined based on
the histologic diagnosis. Cases with no mutation and
benign on histology were considered ‘‘true negative.’’
Cases with a mutation and malignant on histology were
considered ‘‘true positive.’’ The overall accuracy was
determined using all of the genetic alterations in combi-
nation and in a subset analysis excluding those mutations
that may be present in benign thyroid neoplasm (NRAS
and KRAS). The genetic testing was performed blinded to
the FNA biopsy and histologic diagnosis.
Results
We detected 50 mutations in 400 thyroid FNA biopsy
samples (23 BRAF V600E mutations, 21 NRAS mutations,
Table 1 PCR primers for
BRAF, KRAS, and NRAS
hotspot mutation analyses
a Forward, b reverse
Gene Codon Primer sequences (50–30)
KRAS 12/13 a 50-GGCCTGCTGAAAATGACTGAA-30
b 50-GGTCCTGCACCAGTAATATGC-30
KRAS 61 a 50-CAGGATTCCTACAGGAAGCAAGTAG-30
b 50-CACAAAGAAAGCCCTCCCCA-30
NRAS 12/13 a 50-ATGACTGAGTACAAACTGGT-30
b 50-CTCTATGGTGGGATCATATT-30
NRAS 61 a 50-TCTTACAGAAAACAAGTGGT-30
b 50-AGCGGATAACAATTTCACACAGGC CAA AAA TTTAATCAGTGGA-30
BRAF 600 a 50-TGTAAAACGACGGCCAGTCATAATGCTTGCTCTGA TAG GA-30
b 50-AGCGGATAACAATTTCACACAGGCCAA AAATTTAATCAGTGGA-30
World J Surg (2010) 34:2589–2594 2591
123
and 4 RET/PTC1 and 2 RET/PTC3 rearrangements). The
demographics of the study cohort and the interpretation of
the FNA biopsy are summarized in Table 3. One hundred
ten were indeterminate, 27 were suspicious, and 2 were
nondiagnostic. Genetic alterations were significantly more
common in malignant (28%) than in benign (6%) thyroid
nodules (P \ 0.0001). The malignancy rate was 32% in the
indeterminate group, 56% in the suspicious-for-malignancy
group, and 100% for the malignant group, based on per-
manent histologic examination (Fig. 2).
Molecular testing for all the common genetic alterations
in combination had a sensitivity of 38%, specificity of
65%, PPV of 42%, and NPV of 65%. When cases positive
for NRAS mutations were excluded because the mutations
can be present in benign thyroid neoplasm, the sensitivity
was 12% and specificity was 98% (2 false-positive results).
One BRAF V600E mutation was detected in a benign
dominant thyroid nodule that had microscopic papillary
thyroid cancer. One RET/PTC3 rearrangement was detec-
ted in a benign thyroid nodule in the background of chronic
lymphocytic thyroiditis.
In cases with indeterminate and suspicious thyroid FNA
biopsy cytologic diagnosis, 17 cases (12%) were positive
for BRAF V600E mutation and RET/PTC1 or RET/PTC3
rearrangements (Fig. 2). For initial treatment, 5 had a total
thyroidectomy and 12 underwent only a diagnostic thy-
roidectomy. In these 12 cases, the presence of the somatic
mutations specific for papillary thyroid cancer could have
been used to allow a more definitive initial treatment as all
of these patients went on to have a completion thyroidec-
tomy based on the malignant histologic diagnosis.
Discussion
FNA biopsy has remained the most accurate and cost-
effective preoperative diagnostic test to distinguish benign
from malignant thyroid nodules. However, given that up to
30% of thyroid nodule FNA biopsy results are inconclu-
sive, many patients still undergo a diagnostic thyroidec-
tomy to exclude a cancer diagnosis, and they sometimes
need a completion thyroidectomy. Moreover, the number
of patients found to have a thyroid incidentaloma is
increasing, and the number of patients with inconclusive
FNA biopsy results is even larger. For these reasons, new
ways to improve the diagnostic accuracy of thyroid FNA
biopsy have been actively investigated. We used molecular
testing for common somatic mutations in thyroid cancer of
follicular cell origin to determine the accuracy and feasi-
bility of prospectively testing clinical thyroid FNA biopsy
samples. Based on the histologic diagnosis, we found a
significantly higher rate of mutations in malignant than in
benign thyroid neoplasms. However, molecular testing for
a combination of mutations had low sensitivity and speci-
ficity. Exclusion of NRAS mutations increased specificity
but lowered sensitivity. In 137 cases with indeterminate or
Table 2 PCR primers for RET/PTC1, RET/PTC3, and NTRK1 chromosomal rearrangements
Rearrangement Primer sequences (50–30) Nested primer sequences
RET/PTC1 a 50-GCT GGA GAC CTA CAA ACT GA-30 a 50-ACA AAC TGA AGT GCA AGG CA-30
b 50-GTT GCC TTG ACC ACT TTT C-30 b 50-GCC TTG ACC ACT ACT TTT CCA AA-30
RET/PTC3 a 50-AAG CAA ACC TGC CAG TGG-30 a 50-CCT GCC AGT GGT TAT CAA GC-30
b 50-CTT TCA GCA TCT TCA CGG-30 b 50-GGC CAC CGT GGT GTA CCC TG-30
NTRK1 a 50-TGAGCAGATTAGACTGATGG-30 a 50-GCTGCCGAAGAAAAGTACTC-30
b 50-GGAAGAGGCAGGCAAAGAC-30 b 50-TTTCGTCCTTCTTCTCCACC-30
a Forward, b reverse
Table 3 Demographic and clinical characteristics of study cohort
Clinical characteristics Mean ± SD or no.
Age (years) 51 ± 15
Ethnicity/race
White 281
Asian 48
African-American 16
Other 70
Family history of thyroid disease
Yes 48
History of head and neck irradiation
Yes 37
FNA biopsy diagnosisa
Benign 257
Indeterminate 110
Suspicious 27
Malignant 57
Nondiagnostic 2
SD standard deviation
a Indeterminate category included FNA biopsy findings of follicular
or Hu¨rthle cell neoplasm. Suspicious category included FNA biopsy
findings that were suspicious for malignancy (conventional or fol-
licular variant of papillary thyroid cancer)
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suspicious thyroid FNA cytologic diagnosis, 17 cases were
positive for BRAF V600E, RET/PTC1, or RET/PTC3
mutations, and in 12 cases a more definitive initial thy-
roidectomy procedure could have been performed based on
the molecular testing result.
Mutation analysis for single or a combination of somatic
mutations associated with thyroid cancer of follicular cell
origin has been reported to improve the diagnostic accuracy
ranging from 16 to 48% of cases with indeterminate and/or
suspicious thyroid FNA cytologic diagnosis [5–11]. We
found that in 12% of indeterminate and suspicious thyroid
FNA results, mutation analysis could have allowed for a
more definitive initial surgical treatment. The wide range in
diagnostic accuracy improvement associated with molecular
testing of thyroid FNA biopsies could be due to several
reasons, including differences in FNA classification and
diagnosis among centers, different rates of malignancy based
on cytologic categories, thyroid nodule sampling, preserva-
tion of FNA biopsies, and the number of genetic alterations
for which the biopsy was tested. We may also have observed
a lower rate in sensitivity of combined mutation analysis
because the remnant material from the thyroid FNA was used
for molecular testing. Also, RNA was used to detect RET/
PTC and NTRK1 rearrangements which may be expressed
only at low levels, while they are more readily detectable if
genomic DNA was used to detect rearrangements of these
genes. Testing for PAX8/PPARc rearrangement and HRAS
mutation may also improve the sensitivity of molecular
testing, but they are also present in benign follicular tumors
at a relatively high rate and thus were not included in the
panel of genetic alterations tested for in our study.
The strengths of our study are the large study cohort,
prospective and blinded mutation analysis without clinical
knowledge of the cytologic diagnosis, and the use of the
remaining clinical FNA biopsy material. The follow-up time
was not sufficient to determine accurately the false-negative
rate of thyroid FNA biopsy and see if those benign cases with
NRAS mutation would ever progress to a malignant tumor.
Also, the use of RNA instead of DNA may have reduced the
detection rate of gene rearrangements detected but the study
was instituted for a dual purpose of evaluating a multigene
expression assay [17].
In summary, molecular testing for a panel of common
somatic genetic alterations in thyroid FNA biopsy with
indeterminate or suspicious cytologic features is feasible and
could allow for more definitive initial surgical therapy in a
subset of cases. However, the NPV of genetic testing is too
low to reduce the need for a diagnostic thyroidectomy in
patients with indeterminate or suspicious thyroid FNA
biopsies.
Fig. 2 FNA cytology, histologic diagnosis, and mutation analysis
results in thyroid FNA samples. One hundred four FNA samples had
benign cytology and histology of dominant nodule. In these samples,
there was one BRAF V600E mutation in a benign dominant thyroid
nodule that had microscopic papillary thyroid cancer, one RET/PTC3
rearrangement in a benign thyroid nodule in the background of
chronic lymphocytic thyroiditis, and nine NRAS mutations in
adenomatoid nodules. FA follicular adenoma, HCA Hu¨rthle cell
adenoma, HN hyperplastic nodule, FVPTC follicular variant of
papillary thyroid cancer, HCC Hu¨rthle cell carcinoma, PTC papillary
thyroid cancer, MTC medullary thyroid cancer, ATC anaplastic
thyroid cancer
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